PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Clinical evidence
Mixed results: some sources suggest symptoms may be attenuated [PMID:12391713], while a meta-analysis of 13 trials found no difference compared to placebo [PMID:34200727] and other reviews suggest it is likely ineffective [PMID:20000302].
A systematic review found that severity of hot flashes was lower when EPO was administered for less than 6 months compared to placebo, though no significant difference was found in frequency and duration [PMID:39829189].
Current evidence suggests oral EPO does not provide clinically significant improvement [PMID:20000302].
Likely ineffective for the treatment of premenstrual syndrome [PMID:20000302].
Vaginal EPO (2000 mg) showed significantly greater cervical dilation (larger Hegar dilator size) compared to vaginal misoprostol (200 μg) before gynecological surgery [PMID:37102338]. In missed abortion, addition of 2000 mg vaginal EPO to misoprostol showed significant differences in full abortion and cervical dilatation [PMID:38089421].
Safety & adverse effects
Pregnancy & lactation
Evidence summary
PubMed sources
- 1.PMID: 34946512 (2021) — Herbal Products Used in Menopause and for Gynecological Disorders. · Molecules (Basel, Switzerland)
- 2.PMID: 30000954 (2006) — A review of effective herbal medicines in controlling menopausal symptoms. · Electronic physician
- 3.PMID: 20000302 (2009) — Evening primrose oil. · American family physician
- 4.PMID: 34957578 (2022) — An updated review on efficacy and benefits of sweet almond, evening primrose and jojoba oils in skin care applications. · International journal of cosmetic science
- 5.PMID: 21477394 (2011) — Breast pain. · BMJ clinical evidence